<DOC>
	<DOC>NCT00273312</DOC>
	<brief_summary>This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.</brief_summary>
	<brief_title>Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Inclusion criteria: Hepatocellular carcinoma patients with at least 1 previously unirradiated, measurable lesion without any systemic single agent or combination chemotherapy. Previous local therapy is allowed. Exclusion criteria: Additional protocoldefined inclusion/exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced unresectable metastatic hepatocellular carcinoma</keyword>
	<keyword>Liver cancer</keyword>
</DOC>